SLC27A5: A Protein Regulator of Cell Adhesion and Signaling (G10998)

Target Name: SLC27A5

NCBI ID: G10998

SLC27A5

SLC27A5: A Protein Regulator of Cell Adhesion and Signaling

SLC27A5 (VLCSH2) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidney. It is a member of the VH receptor family, which is a subfamily of the T cell receptor (TCR) family. SLC27A5 is also known as VLCSH2, and its full name is VLCSH2 gene.

The SLC27A5 gene was first identified in 2008, and it encodes a protein that is composed of 214 amino acids. The protein has a molecular weight of 21.9 kDa and a calculated pI of 9.95. SLC27A5 is a secreted protein, which means that it is produced in the cell and released into the surrounding medium, such as the bloodstream or the extracellular matrix (ECM).

SLC27A5 is involved in many different cellular processes in the body, including cell signaling, cell adhesion, and transcriptional regulation. It is a key regulator of the vom hormone (VH) receptor, which is a G protein-coupled receptor that is involved in many different signaling pathways in the body.

One of the most significant functions of SLC27A5 is its role in the regulation of cell adhesion. SLC27A5 is a critical regulator of tight junctions (TJs), which are specialized barriers that mediate the separation of cells in tissues. TJs are composed of transmembrane proteins that are involved in cell signaling, and they help to maintain the integrity of tissues by preventing cells from coming into direct contact with each other.

SLC27A5 is also involved in the regulation of cell signaling. It is a negative regulator of the T cell receptor (TCR), which is a critical regulator of cell growth, differentiation, and survival. SLC27A5 helps to ensure that the TCR is not activated in response to VH signals, which can be either from the brain or from other sources.

SLC27A5 is also involved in transcriptional regulation. It is a regulator of the imprinted transcription factor (ITF), which is a protein that is involved in the regulation of gene expression. SLC27A5 helps to ensure that ITF is not activated in response to VH signals, which can be either from the brain or from other sources.

SLC27A5 is also involved in the regulation of cellular stress responses. It is a regulator of the stress-induced gene expression (SIGER) pathway, which is involved in the regulation of cellular stress responses. SLC27A5 helps to ensure that the SIGER pathway is not activated in response to VH signals, which can be either from the brain or from other sources.

SLC27A5 is also involved in the regulation of inflammation. It is a regulator of the Transcription Factor-1 (TF-1), which is involved in the regulation of cellular inflammation. SLC27A5 helps to ensure that TF-1 is not activated in response to VH signals, which can be either from the brain or from other sources.

SLC27A5 is also involved in the regulation of the efficacy of drugs. It is a predictor of drug sensitivity in cancer cells, which means that cells that have high levels of SLC27A5 will be more resistant to certain drugs. This is because high levels of SLC27A5 may indicate that cells have a high number of replication errors in their DNA, which can make them more resistant to drugs.

In addition to its role in cell signaling, SLC27A5 is also involved in the regulation of cellular processes that are

Protein Name: Solute Carrier Family 27 Member 5

Functions: May mediate the import of long-chain fatty acids (LCFA) by facilitating their transport across cell membranes (PubMed:20448275, PubMed:20530735). Also catalyzes the ATP-dependent formation of fatty acyl-CoA using LCFA and very-long-chain fatty acids (VLCFA) as substrates (PubMed:10479480). Mainly functions as a bile acyl-CoA synthetase catalyzing the activation of bile acids via ATP-dependent formation of bile acid CoA thioesters which is necessary for their subsequent conjugation with glycine or taurine (PubMed:10749848, PubMed:11980911). Both primary bile acids (cholic acid and chenodeoxycholic acid) and secondary bile acids (deoxycholic acid and lithocholic acid) are the principal substrates (PubMed:10749848, PubMed:11980911). In vitro, activates 3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholestanate ((25R)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oate or THCA), the C27 precursor of cholic acid deriving from the de novo synthesis from cholesterol (PubMed:11980911). Plays an important role in hepatic fatty acid uptake and bile acid reconjugation and recycling but not in de novo synthesis of bile acids (By similarity)

The "SLC27A5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC27A5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets